- Home
- ALLO vs RLTY Comparison
ALLO vs RLTY Comparison
Compare ALLO & RLTY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ALLO | RLTY |
|---|---|---|
| Founded | 2017 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 252.9M | 247.3M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | ALLO | RLTY |
|---|---|---|
| Price | $1.50 | $14.72 |
| Analyst Decision | Buy | |
| Analyst Count | 11 | 0 |
| Target Price | ★ $8.67 | N/A |
| AVG Volume (30 Days) | ★ 2.4M | 86.7K |
| Earning Date | 11-06-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.35% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $100.00 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.86 | $11.38 |
| 52 Week High | $3.78 | $14.60 |
Technical Indicators
Market Signals| Indicator | ALLO | RLTY |
|---|---|---|
| Relative Strength Index (RSI) | 61.26 | 37.46 |
| Support Level | $1.39 | $14.88 |
| Resistance Level | $1.52 | $15.20 |
| Average True Range (ATR) | 0.10 | 0.19 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 87.50 | 14.93 |
Price Performance
Historical ComparisonAbout ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.
About RLTY Cohen & Steers Real Estate Opportunities and Income Fund of Beneficial Interest
Cohen & Steers Real Estate Opportunities and Income Fund is an organized, non-diversified, closed-end management investment company. The Fund's primary investment objective is high current income. The Fund's secondary investment objective is capital appreciation.